12/26/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – natalizumab

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Natalizumab

Natalizumab

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Moritz MJ et al. Transplant Pregnancy Register International. 2016 Annual Report.

  2. Deshpande NA, Coscia LA, Gomez-Lobo V, Moritz MJ, Armenti VT. Pregnancy after solid organ transplantation: a guide for obstetric management. Rev Obstet Gynecol. 2013;6:116-25.

  3. Coscia LA, Constantinescu S, Moritz MJ, Frank AM, Ramirez CB, Maley WR et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation Clin Transpl. 2010;65-68.

  4. Armenti VT, Constantinescu S, Moritz MJ, Davison JM Pregnancy after transplantation. Transplantation Reviews 2008;22:223-240.

  5. Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71:891-5.

  6. Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy A prospective, controlled observational study. Mult Scler. 2015;21:198-205.

  7. Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016;16:150.

  8. Demortiere S, Rico A, Maarouf A, Boutiere C, Pelletier J, Audoin B. Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis. Mult Scler. 2021;5(0):712-718.

  9. Landi D, Bovis F, Grimaldi A, Annovazzi PO, Bertolotto A, Bianchi A et al. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022.

  1. Moritz MJ et al. Transplant Pregnancy Register International. 2016 Annual Report.
  2. Deshpande NA, Coscia LA, Gomez-Lobo V, Moritz MJ, Armenti VT. Pregnancy after solid organ transplantation: a guide for obstetric management. Rev Obstet Gynecol. 2013;6:116-25.
  3. Coscia LA, Constantinescu S, Moritz MJ, Frank AM, Ramirez CB, Maley WR et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation Clin Transpl. 2010;65-68.
  4. Armenti VT, Constantinescu S, Moritz MJ, Davison JM Pregnancy after transplantation. Transplantation Reviews 2008;22:223-240.
  5. Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71:891-5.
  6. Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy A prospective, controlled observational study. Mult Scler. 2015;21:198-205.
  7. Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016;16:150.
  8. Demortiere S, Rico A, Maarouf A, Boutiere C, Pelletier J, Audoin B. Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis. Mult Scler. 2021;5(0):712-718.
  9. Landi D, Bovis F, Grimaldi A, Annovazzi PO, Bertolotto A, Bianchi A et al. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022.